Compare ASG & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASG | SLN |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 88 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 341.5M | 300.9M |
| IPO Year | 1995 | N/A |
| Metric | ASG | SLN |
|---|---|---|
| Price | $5.42 | $9.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | 189.7K | ★ 627.9K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.55 | $4.19 |
| 52 Week High | $5.69 | $11.06 |
| Indicator | ASG | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 58.59 |
| Support Level | $5.39 | $5.87 |
| Resistance Level | $5.57 | $11.06 |
| Average True Range (ATR) | 0.09 | 0.89 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 57.45 | 60.33 |
Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company's portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.